In this study, the anti–severe acute respiratory syndrome coronavirus‐2 (anti‐SARS‐CoV‐2) activity of mycophenolic acid (MPA) and IMD‐0354 was analyzed. These compounds were chosen based on their antiviral activities against other coronaviruses. Because they also inhibit dengue virus (DENV) infection, other anti‐DENV compounds/drugs were also assessed. On SARS‐CoV‐2‐infected VeroE6/TMPRSS2 monolayers, both MPA and IMD‐0354, but not other anti‐DENV compounds/drugs, showed significant anti‐SARS‐CoV‐2 activity. Although MPA reduced the viral RNA level by only approximately 100‐fold, its half maximal effective concentration was as low as 0.87 µ m, which is easily achievable at therapeutic doses of mycophenolate mofetil. MPA targets the coronaviral papain‐like protease and an in‐depth study on its mechanism of action would be useful in the development of novel anti‐SARS‐CoV‐2 drugs.

中文翻译：

---

霉酚酸和 IMD-0354 对 SARS-CoV-2 的抗病毒活性。

在这项研究中，分析了霉酚酸 (MPA) 和 IMD-0354 的抗严重急性呼吸综合征冠状病毒-2（抗 SARS-CoV-2）活性。这些化合物的选择是基于它们对其他冠状病毒的抗病毒活性。因为它们还抑制登革病毒 (DENV) 感染，所以还评估了其他抗 DENV 化合物/药物。在 SARS-CoV-2 感染的 VeroE6/TMPRSS2 单层上，MPA 和 IMD-0354，但不是其他抗 DENV 化合物/药物，都显示出显着的抗 SARS-CoV-2 活性。尽管 MPA 仅将病毒 RNA 水平降低了约 100 倍，但其半数最大有效浓度低至 0.87 µm，在治疗剂量的吗替麦考酚酯下很容易实现。MPA 靶向冠状病毒木瓜蛋白酶样蛋白酶，对其作用机制的深入研究将有助于开发新型抗 SARS-CoV-2 药物。